Aims Digoxin is frequently used for rate control of atrial fibrillation (AF). It has, however, been
associated with increased mortality. It remains unclear whether digoxin itself is responsible …

Post hoc analyses of the Digitalis Investigation Group (DIG) trial indicate that digoxin at low
(0.5 to 0.9 ng/ml) serum digoxin concentration (SDC) reduces mortality, which is eliminated …

Objectives: We sought to determine whether there was a relationship between serum
digoxin concentration (SDC), including SDCs typically regarded as low, and clinical efficacy …

Background—Clinical guidelines recommend digoxin for patients with symptomatic systolic
heart failure (HF) receiving optimal medical therapy, but this recommendation is based on …

Context The Digitalis Investigation Group (DIG) trial reported that digoxin provided no overall
mortality benefit and only a modest reduction in hospitalizations among patients with heart …

Background The role of cardiac glycosides in treating patients with chronic heart failure and
normal sinus rhythm remains controversial. We studied the effect of digoxin on mortality and …

Background The Digitalis Investigation Group trial reported that treatment with digoxin did
not decrease overall mortality among patients with heart failure and depressed left …

Evidence-based medicine is an evolutionary process, intended to foster and disseminate the
best practice guidelines from an ongoing critical analysis of available data. An …

Renal dysfunction is a common complication for patients with heart failure, but its
association with clinical outcomes has not been fully characterized. We evaluated the …

OBJECTIVES This study was designed to determine the effect of increasing age on mortality,
hospitalizations and digoxin side effects in patients with heart failure (HF), and to determine …